We found that the mutation rate of MUC19 in lung cancer was higher in Asian patients than in non-Asian patients (LUSC-KR 63.53% vs. LUSC-US 5.15%; LUSC-US 5.15% vs. LUAD-US 1.16%). Here, MUC19 is linked to lung carcinoma.